Why do some lung cancer patients respond to immunotherapy while others do not? Multimodal genomic features recently published in Nature Cancer may help identify patients that benefit most from immune checkpoint blockade. https://t.co/ig8VZOQAy7
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @jjdmochon: @isliquidbiopsy @ChristianRolfo @MCristofanill @MJOSESERRANO19 @jlorentegrx
@isliquidbiopsy @ChristianRolfo @MCristofanill @MJOSESERRANO19 @jlorentegrx
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer - https://t.co/6NfJhJ3Wzc
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
RT @EricTopol: So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P…
So much effort to predict which patients will respond to #cancer immunotherapy —circulating tumor DNA https://t.co/KmfjFS8P8l —multi-omics & "tumor purity" https://t.co/2G1Ieefl4b @NatureCancer by @StanfordMed @sloan_kettering @HopkinsMedicine @Steven
LUNG: correcting for tumour cellularity can improve the power of tumour mutational burden to identify immunotherapy responders. Signalling receptor mutations were associated with lack of response to immunotherapy in NSCLC. https://t.co/5GnTpcBLDd
"we found a significant correlation between tumor mutation burden (TMB) and tumor purity, suggesting that low tumor purity tumors are likely to have inaccurate TMB estimates" ⚠️⚠️
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer | Nature Cancer https://t.co/fYhuVhZI3L
RT @NatRevClinOncol: Multimodal genomic features predict outcome of immune checkpoint blockade in NSCLC: https://t.co/NvyUwmjdKT #LCSM #Imm…
RT @FordePatrick: Outstanding effort led by @ValsamoA & incorporating our entire lung cancer program over the last 5 years. Thanks to the m…
RT @NatureCancer: 📡 Some #Cancer #Immunotherapies @NatureCancer ‼️ @ValsamoA dissects multimodal genomic features to predict immune checkp…
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer | Nature Cancer https://t.co/83bbgJ6BWH
RT @NatRevClinOncol: Multimodal genomic features predict outcome of immune checkpoint blockade in NSCLC: https://t.co/NvyUwmjdKT #LCSM #Imm…
RT @NatRevClinOncol: Multimodal genomic features predict outcome of immune checkpoint blockade in NSCLC: https://t.co/NvyUwmjdKT #LCSM #Imm…
RT @Zihai: Nice work. Congrats! Especially impressed with the finding that genomic alterations in RTK genes including EGFR, HER2, MET, FGFR…
RT @NatRevClinOncol: Multimodal genomic features predict outcome of immune checkpoint blockade in NSCLC: https://t.co/NvyUwmjdKT #LCSM #Imm…
RT @NatRevClinOncol: Multimodal genomic features predict outcome of immune checkpoint blockade in NSCLC: https://t.co/NvyUwmjdKT #LCSM #Imm…
Multimodal genomic features predict outcome of immune checkpoint blockade in NSCLC: https://t.co/NvyUwmjdKT #LCSM #ImmunoOnc
RT @miyatamitsuru: TMBが試料中の癌細胞の割合に左右される。それを補正したTMB7が、免疫チェックポイント阻害剤の効果をより正確に予測できるらしい。 Multimodal genomic features predict outcome of immune…
RT @NatureCancer: 📡 Some #Cancer #Immunotherapies @NatureCancer ‼️ @ValsamoA dissects multimodal genomic features to predict immune checkp…
RT @NatureCancer: 📡 Some #Cancer #Immunotherapies @NatureCancer ‼️ @ValsamoA dissects multimodal genomic features to predict immune checkp…
RT @ValsamoA: Behind the scenes story of our journey with integrative analyses to elucidate the genomic wiring of response to #immunotherap…
Multimodal genomic features predict outcome of ICB, including HLA class I heterozygosity
RT @NatureCancer: 📡 Some #Cancer #Immunotherapies @NatureCancer ‼️ @ValsamoA dissects multimodal genomic features to predict immune checkp…
RT @Zihai: Nice work. Congrats! Especially impressed with the finding that genomic alterations in RTK genes including EGFR, HER2, MET, FGFR…
Nice work. Congrats! Especially impressed with the finding that genomic alterations in RTK genes including EGFR, HER2, MET, FGFR1 and IGF1R are linked with primary resistance to ICB independent of mutation burden.
RT @miyatamitsuru: TMBが試料中の癌細胞の割合に左右される。それを補正したTMB7が、免疫チェックポイント阻害剤の効果をより正確に予測できるらしい。 Multimodal genomic features predict outcome of immune…
RT @miyatamitsuru: さらに多種のオミックス解析などを加えれば精度が向上する。
RT @diegochowell: Happy to see this paper validating the influence of both HLA-I genetic variation and TMB to predict immune checkpoint bl…
RT @ValsamoA: Excited to see the inaugural issue of @NatureCancer and our study Multimodal Genomic Features Predict Outcome To Immunotherap…
さらに多種のオミックス解析などを加えれば精度が向上する。
TMBが試料中の癌細胞の割合に左右される。それを補正したTMB7が、免疫チェックポイント阻害剤の効果をより正確に予測できるらしい。 Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer | Nature Cancer https://t.co/HriIFqEnOL
RT @ValsamoA: Excited to see the inaugural issue of @NatureCancer and our study Multimodal Genomic Features Predict Outcome To Immunotherap…
RT @NatureCancer: 📡 Some #Cancer #Immunotherapies @NatureCancer ‼️ @ValsamoA dissects multimodal genomic features to predict immune checkp…
RT @NatureCancer: 📡 Some #Cancer #Immunotherapies @NatureCancer ‼️ @ValsamoA dissects multimodal genomic features to predict immune checkp…
RT @NatureCancer: 📡 Some #Cancer #Immunotherapies @NatureCancer ‼️ @ValsamoA dissects multimodal genomic features to predict immune checkp…
RT @ValsamoA: Behind the scenes story of our journey with integrative analyses to elucidate the genomic wiring of response to #immunotherap…
RT @ValsamoA: Excited to see the inaugural issue of @NatureCancer and our study Multimodal Genomic Features Predict Outcome To Immunotherap…
@alanlparker
RT @ValsamoA: Excited to see the inaugural issue of @NatureCancer and our study Multimodal Genomic Features Predict Outcome To Immunotherap…
RT @NatureCancer: 📡 Some #Cancer #Immunotherapies @NatureCancer ‼️ @ValsamoA dissects multimodal genomic features to predict immune checkp…
RT @ValsamoA: Behind the scenes story of our journey with integrative analyses to elucidate the genomic wiring of response to #immunotherap…
RT @ValsamoA: Behind the scenes story of our journey with integrative analyses to elucidate the genomic wiring of response to #immunotherap…
RT @ValsamoA: Behind the scenes story of our journey with integrative analyses to elucidate the genomic wiring of response to #immunotherap…
RT @ValsamoA: Behind the scenes story of our journey with integrative analyses to elucidate the genomic wiring of response to #immunotherap…
Behind the scenes story of our journey with integrative analyses to elucidate the genomic wiring of response to #immunotherapy in #lungcancer. @hopkinskimmel @bloombergkimmel with @velculescu @FordePatrick @DrJNaidoo @benlevylungdoc https://t.co/QuRfOPvcS
RT @NatureCancer: 📡 Some #Cancer #Immunotherapies @NatureCancer ‼️ @ValsamoA dissects multimodal genomic features to predict immune checkp…
@alanlparker
RT @NatureCancer: 📡 Some #Cancer #Immunotherapies @NatureCancer ‼️ @ValsamoA dissects multimodal genomic features to predict immune checkp…
RT @diegochowell: Happy to see this paper validating the influence of both HLA-I genetic variation and TMB to predict immune checkpoint bl…
RT @NatureCancer: 📡 Some #Cancer #Immunotherapies @NatureCancer ‼️ @ValsamoA dissects multimodal genomic features to predict immune checkp…
RT @ValsamoA: Excited to see the inaugural issue of @NatureCancer and our study Multimodal Genomic Features Predict Outcome To Immunotherap…
RT @NatureCancer: 📡 Some #Cancer #Immunotherapies @NatureCancer ‼️ @ValsamoA dissects multimodal genomic features to predict immune checkp…
Happy to see this paper validating the influence of both HLA-I genetic variation and TMB to predict immune checkpoint blockade response.
RT @NatureCancer: 📡 Some #Cancer #Immunotherapies @NatureCancer ‼️ @ValsamoA dissects multimodal genomic features to predict immune checkp…
RT @NatureCancer: 📡 Some #Cancer #Immunotherapies @NatureCancer ‼️ @ValsamoA dissects multimodal genomic features to predict immune checkp…
RT @NatureCancer: 📡 Some #Cancer #Immunotherapies @NatureCancer ‼️ @ValsamoA dissects multimodal genomic features to predict immune checkp…
RT @NatureCancer: 📡 Some #Cancer #Immunotherapies @NatureCancer ‼️ @ValsamoA dissects multimodal genomic features to predict immune checkp…
RT @NatureCancer: 📡 Some #Cancer #Immunotherapies @NatureCancer ‼️ @ValsamoA dissects multimodal genomic features to predict immune checkp…
📡 Some #Cancer #Immunotherapies @NatureCancer ‼️ @ValsamoA dissects multimodal genomic features to predict immune checkpoint blockade response, explaining the lack of power of individual feats such as PDL1 expression, HLA, or TMB alone. Check it out: htt
RT @ValsamoA: Excited to see the inaugural issue of @NatureCancer and our study Multimodal Genomic Features Predict Outcome To Immunotherap…
RT @ValsamoA: Excited to see the inaugural issue of @NatureCancer and our study Multimodal Genomic Features Predict Outcome To Immunotherap…
RT @FordePatrick: Outstanding effort led by @ValsamoA & incorporating our entire lung cancer program over the last 5 years. Thanks to the m…
RT @FordePatrick: Outstanding effort led by @ValsamoA & incorporating our entire lung cancer program over the last 5 years. Thanks to the m…
RT @ValsamoA: Excited to see the inaugural issue of @NatureCancer and our study Multimodal Genomic Features Predict Outcome To Immunotherap…
RT @josephcmurray: Depth and breadth in cancer genomics and immunotherapy in NSCLC, out in @NatureCancer led by my mentor, Dr. @ValsamoA! L…
RT @FordePatrick: Outstanding effort led by @ValsamoA & incorporating our entire lung cancer program over the last 5 years. Thanks to the m…
TMB didn’t have a great year in 2019; does this represent a comeback in 2020 (integrated with key genomics)? Great work. #OncoAlert
RT @FordePatrick: Outstanding effort led by @ValsamoA & incorporating our entire lung cancer program over the last 5 years. Thanks to the m…
RT @FordePatrick: Outstanding effort led by @ValsamoA & incorporating our entire lung cancer program over the last 5 years. Thanks to the m…
RT @josephcmurray: Depth and breadth in cancer genomics and immunotherapy in NSCLC, out in @NatureCancer led by my mentor, Dr. @ValsamoA! L…
RT @josephcmurray: Depth and breadth in cancer genomics and immunotherapy in NSCLC, out in @NatureCancer led by my mentor, Dr. @ValsamoA! L…
Outstanding effort led by @ValsamoA & incorporating our entire lung cancer program over the last 5 years. Thanks to the many patients who participated! Comprehensive genomic analyses rigorously applied to predict those pts most likely to benefit from I
Depth and breadth in cancer genomics and immunotherapy in NSCLC, out in @NatureCancer led by my mentor, Dr. @ValsamoA! Lucky to learn from her and our entire #UAD Thoracic Oncology group @hopkinskimmel. Eager to contribute #lcsm!
RT @ValsamoA: Excited to see the inaugural issue of @NatureCancer and our study Multimodal Genomic Features Predict Outcome To Immunotherap…
RT @ValsamoA: Excited to see the inaugural issue of @NatureCancer and our study Multimodal Genomic Features Predict Outcome To Immunotherap…
Excited to see the inaugural issue of @NatureCancer and our study Multimodal Genomic Features Predict Outcome To Immunotherapy go live! @hopkinskimmel #UADResearchGroup https://t.co/UJt6GjDkeD